menu
    • menu

    Company profile for AceLink Therapeutics

    NEW Drugs in Dev: 3
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AceLink Therapeutics is a clinical-stage drug development company that leverages deep understanding of glycolipid biology to develop groundbreaking therapies for genetic diseases and kidney diseases. AceLink consists of a seasoned team of drug development professionals, consultants, and advisors with a rich knowledge of glycolipid biology, kidney disease, and drug development. We collaborate with an experienced network of ...
    AceLink Therapeutics is a clinical-stage drug development company that leverages deep understanding of glycolipid biology to develop groundbreaking therapies for genetic diseases and kidney diseases. AceLink consists of a seasoned team of drug development professionals, consultants, and advisors with a rich knowledge of glycolipid biology, kidney disease, and drug development. We collaborate with an experienced network of contract research organizations, academics, and key opinion leaders (KOLs). This model allows us to efficiently transform scientific discoveries into impactful new therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AceLink TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    39600 Eureka Drive, Suite 151, Newark, CA 94560
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://acelinktherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CGT Asia

    Not Confirmed

    envelop Contact Supplier

    CGT Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AceLink Completes 6-Month Primary Ph of AL01211 in Fabry
    AceLink Completes 6-Month Primary Ph of AL01211 in Fabry

    14 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250814528346/en/AceLink-Therapeutics-Completes-6-Month-Primary-Phase-of-AL01211-Clinical-Study-in-Fabry-Disease-Patients

    BUSINESSWIRE
    14 Aug 2025
    Share Share
    AceLink Presents Results for AL01211 in Fabry Disease Patients
    AceLink Presents Results for AL01211 in Fabry Disease Patients

    07 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250207924380/en

    BUSINESSWIRE
    07 Feb 2025
    Share Share
    AceLink Announces Publication of Phase 1 Trial Data Evaluating AL01211
    AceLink Announces Publication of Phase 1 Trial Data Evaluating AL01211

    26 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240226569957/en

    BUSINESSWIRE
    26 Feb 2024
    Share Share
    AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211
    AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211

    31 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231031050670/en

    BUSINESSWIRE
    31 Oct 2023
    Share Share
    AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease
    AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease

    10 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230810290371/en

    BUSINESSWIRE
    10 Aug 2023
    Share Share
    AceLink Therapeutics approved to begin Fabry disease drug trial
    AceLink Therapeutics approved to begin Fabry disease drug trial

    22 Jun 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/acelink-therapeutics-fabry-disease/

    CLINICAL TRIALS ARENA
    22 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search